BLFS:NSD-BioLife Solutions, Inc (USD)

COMMON STOCK | Medical Instruments & Supplies | NSD

Last Closing Price

USD 41.98

Change

+0.61 (+1.47)%

Market Cap

USD 1.35B

Volume

0.32M

Average Target Price

USD 35.11 (-16.36%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools for the cell and gene therapy industry in North America, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; and the ThawSTAR line that includes automated vial and cryobag thawing products that control the heat and timing of the thawing process of biologic materials. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; and liquid nitrogen laboratory freezers, cryogenic equipment, and accessories. The company markets and sells its products directly, as well as through third party distributors. BioLife Solutions, Inc. was founded in 1987 and is headquartered in Bothell, Washington. Address: 3303 Monte Villa Parkway, Bothell, WA, United States, 98021

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-01-25 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ISRG Intuitive Surgical, Inc

+7.93 (+1.07%)

USD87.47B 84.36 76.78
HOLX Hologic, Inc

+0.64 (+0.85%)

USD19.51B 17.98 14.69
NVCR NovoCure Limited

-1.91 (-1.13%)

USD17.21B 919.02 503.82
MASI Masimo Corporation

-6.59 (-2.50%)

USD14.52B 68.49 47.43
XRAY DENTSPLY SIRONA Inc

-0.22 (-0.38%)

USD12.51B 126.19 43.33
RGEN Repligen Corporation

-4.04 (-1.84%)

USD12.00B 265.84 135.57
IRTC iRhythm Technologies, Inc

-8.12 (-3.21%)

USD7.30B N/A N/A
ICUI ICU Medical, Inc

+1.05 (+0.48%)

USD4.63B 58.38 23.61
STAA STAAR Surgical Company

-1.60 (-1.75%)

USD4.21B 483.44 502.00
MMSI Merit Medical Systems, Inc

+0.39 (+0.67%)

USD3.19B 379.20 42.66

ETFs Containing BLFS

Symbol Name Weight Mer Price(Change) Market Cap

Market Performance

  Market Performance vs.
Industry/Classification (Medical Instruments & Supplies)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 5.24% 42% F 45% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 5.24% 42% F 45% F
Trailing 12 Months  
Capital Gain 180.43% 97% A+ 90% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 180.43% 97% A+ 90% A-
Trailing 5 Years  
Capital Gain 2,169.07% 100% A+ 98% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 2,169.07% 100% A+ 98% A+
Average Annual (5 Year Horizon)  
Capital Gain 117.85% 100% A+ 97% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 117.85% 100% A+ 97% A+
Risk Return Profile  
Volatility (Standard Deviation) 128.48% 19% F 8% F
Risk Adjusted Return 91.73% 78% C+ 91% A-
Market Capitalization 1.35B 65% D 69% D+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Instruments & Supplies)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 350.59 22% F 5% F
Price/Book Ratio 7.07 39% F 25% F
Price / Cash Flow Ratio 1,116.47 3% F 0% N/A
EV/EBITDA 114.10 23% F 9% F
Management Effectiveness  
Return on Equity 5.90% 71% C- 65% D
Return on Invested Capital 3.05% 58% F 56% F
Return on Assets -0.70% 45% F 43% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 2.84 68% D+ 46% F
Short Percent 3.90% 48% F 45% F
Beta 1.55 29% F 29% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector